Nouveau Life Pharmaceuticals Stock Working Capital
| NOUV Stock | USD 0.0001 0.0001 50.00% |
Nouveau Life Pharmaceuticals fundamentals help investors to digest information that contributes to Nouveau Life's financial success or failures. It also enables traders to predict the movement of Nouveau Pink Sheet. The fundamental analysis module provides a way to measure Nouveau Life's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Nouveau Life pink sheet.
Nouveau |
Nouveau Life Pharmaceuticals Company Working Capital Analysis
Nouveau Life's Working Capital is a measure of company efficiency and operating liquidity. The working capital is usually calculated by subtracting Current Liabilities from Current Assets. It is an important indicator of the firm ability to continue its normal operations without additional debt obligations. .
More About Working Capital | All Equity Analysis
Working Capital | = | Current Assets | - | Current Liabilities |
Current Nouveau Life Working Capital | (145 K) |
Most of Nouveau Life's fundamental indicators, such as Working Capital, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Nouveau Life Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Working Capital can be positive or negative, depending on how much of current debt the company is carrying on its balance sheet. In general terms, companies that have a lot of working capital will experience more growth in the near future since they can expand and improve their operations using existing resources. On the other hand, companies with small or negative working capital may lack the funds necessary for growth or future operation. Working Capital also shows if the company has sufficient liquid resources to satisfy short-term liabilities and operational expenses.
| Competition |
Based on the company's disclosures, Nouveau Life Pharmaceuticals has a Working Capital of (145,000). This is 100.0% lower than that of the Financial Services sector and significantly lower than that of the Shell Companies industry. The working capital for all United States stocks is 100.01% higher than that of the company.
Nouveau Working Capital Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Nouveau Life's direct or indirect competition against its Working Capital to detect undervalued stocks with similar characteristics or determine the pink sheets which would be a good addition to a portfolio. Peer analysis of Nouveau Life could also be used in its relative valuation, which is a method of valuing Nouveau Life by comparing valuation metrics of similar companies.Nouveau Life is currently under evaluation in working capital category among its peers.
Nouveau Fundamentals
| Return On Equity | -2.2 | |||
| Return On Asset | -0.2 | |||
| Current Valuation | 722.68 K | |||
| Price To Earning | (0.01) X | |||
| Price To Book | 22.72 X | |||
| EBITDA | (163.87 K) | |||
| Net Income | (357.25 K) | |||
| Cash And Equivalents | 1.1 K | |||
| Cash Flow From Operations | (22.91 K) | |||
| Earnings Per Share | (0.02) X | |||
| Beta | -4.22 | |||
| Market Capitalization | 484.8 K | |||
| Total Asset | 1.33 M | |||
| Retained Earnings | (236 K) | |||
| Working Capital | (145 K) | |||
| Current Asset | 1 K | |||
| Current Liabilities | 146 K | |||
| Net Asset | 1.33 M |
About Nouveau Life Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Nouveau Life Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Nouveau Life using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Nouveau Life Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Nouveau Pink Sheet Analysis
When running Nouveau Life's price analysis, check to measure Nouveau Life's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Nouveau Life is operating at the current time. Most of Nouveau Life's value examination focuses on studying past and present price action to predict the probability of Nouveau Life's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Nouveau Life's price. Additionally, you may evaluate how the addition of Nouveau Life to your portfolios can decrease your overall portfolio volatility.